Literature DB >> 8346731

Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents.

B N Singh1.   

Abstract

Although synthesized as a nonselective beta-adrenergic blocking compound, sotalol has emerged as the prototype of the so-called class III antiarrhythmic compounds. It delays cardiac repolarization by inhibiting the delayed rectifier potassium current, having a lesser effect on the inward rectifying potassium current with little or no effect on the inward calcium or sodium currents. This property of prolonging repolarization with an accompanying increase in the effective refractory period is not due to blockade of the beta-adrenergic receptors. The major electrophysiologic profile of sotalol constitutes the summed effects of beta blockade and prolonged repolarization. Sotalol exerts a potent antifibrillatory action modulated by its antiadrenergic effects. It suppresses premature ventricular contractions and nonsustained ventricular tachycardia while preventing inducible ventricular tachycardia and fibrillation in patients with advanced structural heart disease. The compound is therefore likely to exert a broad spectrum of antiarrhythmic actions in ventricular arrhythmias.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8346731     DOI: 10.1016/0002-9149(93)90020-d

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

1.  d,l-Sotalol at therapeutic concentrations facilitates the occurrence of long-lasting non-stationary reentry during ventricular fibrillation in isolated rabbit hearts.

Authors:  Yu-Cheng Hsieh; Tzyy-Leng Horng; Shien-Fong Lin; Tung-Chao Lin; Chih-Tai Ting; Tsu-Juey Wu
Journal:  Circ J       Date:  2008-11-13       Impact factor: 2.993

2.  Molecular determinants of pro-arrhythmia proclivity of d- and l-sotalol via a multi-scale modeling pipeline.

Authors:  Kevin R DeMarco; Pei-Chi Yang; Vikrant Singh; Kazuharu Furutani; John R D Dawson; Mao-Tsuen Jeng; James C Fettinger; Slava Bekker; Van A Ngo; Sergei Y Noskov; Vladimir Yarov-Yarovoy; Jon T Sack; Heike Wulff; Colleen E Clancy; Igor Vorobyov
Journal:  J Mol Cell Cardiol       Date:  2021-05-29       Impact factor: 5.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.